Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory to Standard Therapies”

201 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 201 results

Early research (Phase 1)Study completedNCT00027898
What this trial is testing

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 27
Large-scale testing (Phase 3)Ended earlyNCT00184548
What this trial is testing

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

Who this might be right for
Acquired Bleeding DisorderTrauma
Novo Nordisk A/S 554
Early research (Phase 1)Study completedNCT00607724
What this trial is testing

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Genentech, Inc. 68
Early research (Phase 1)Study completedNCT01397799
What this trial is testing

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myelogenous Leukemia
Kinex Pharmaceuticals Inc. 24
Testing effectiveness (Phase 2)Study completedNCT03839446
What this trial is testing

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Who this might be right for
Acute Myeloid Leukemia
Robert Redner, MD 16
Early research (Phase 1)UnknownNCT05989724
What this trial is testing

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorBreast CancerPancreatic Cancer+2 more
Qurgen Inc. 150
Not applicableEnded earlyNCT06572839
What this trial is testing

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Who this might be right for
Diabetic Foot Ulcer
Capsicure, LLC 74
Early research (Phase 1)Looking for participantsNCT06873659
What this trial is testing

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorGastric CancerLiver Cancer
Qurgen Inc. 96
Testing effectiveness (Phase 2)UnknownNCT00081536
What this trial is testing

Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Who this might be right for
Colorectal Neoplasms
Aronex Pharmaceuticals 105
Testing effectiveness (Phase 2)Ended earlyNCT00001880
What this trial is testing

Stem Cell Transplantation for Metastatic Solid Tumors

Who this might be right for
Neoplasm Metastasis
National Heart, Lung, and Blood Institute (NHLBI) 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07254637
What this trial is testing

Tocilizumab in Chronic Inflammatory CPPD Disease

Who this might be right for
Calcium Pyrophosphate Deposition Disease
Assistance Publique - Hôpitaux de Paris 80
Testing effectiveness (Phase 2)UnknownNCT04640246
What this trial is testing

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Who this might be right for
CancerTumor, SolidRefractory Cancer
Taiga Biotechnologies, Inc. 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06413498
What this trial is testing

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Kite, A Gilead Company 452
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Not applicableNo Longer AvailableNCT00210665
What this trial is testing

Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Who this might be right for
Sarcoma
Janssen Research & Development, LLC
Large-scale testing (Phase 3)Active Not RecruitingNCT04579224
What this trial is testing

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+2 more
National Cancer Institute (NCI) 184
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Study completedNCT00968981
What this trial is testing

Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 67
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Next Page